Karl Peter Schwarz, general manager of the Austrian affiliate of LEO Pharma, an ambitious Danish company leading the way in innovative dermatology treatments, provides an in-depth look into how global partnerships and acquisitions have impacted the strategies and operations of the Austrian affiliate. Equally, he provides an insight into how LEO Pharma’s cutting-edge drugs are positively effecting lives and what being a patient-centric company really means.
LEO Pharma CEO, Gitte Aabo, has put forward an ambitious 2020 plan to bring the company to the forefront of the dermatology world and thus far there have been some headline partnerships and acquisitions to bolster this push. How have these activities at a global level trickled down to the local Austrian affiliate?
"Even at a local level we have built on a strong relationship with our diversifying partners, and this has heavily contributed to our patient-centric approach."
